The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

But in the case of Medicare and Medicaid, which together make up roughly a quarter of total federal spending, the fraud is real and substantial. Where the money is Billions are improperly paid out ...

as costs declined and the exit from certain “unprofitable” Medicare Advantage plans progressed. While the company also affirmed its full-year profit outlook, which can be viewed as a positive ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now she fears a deal struck between CVS Health Corp. and Novo Nordisk A/S will ...

Because it is approved to treat sleep apnea, Medicare covers Zepbound for that purpose. It does not cover it solely for weight loss. Patients paying the list price for the medication would pay ...

Credit: Getty Images With the FDA approval of Zepbound (tirzepatide) for obstructive sleep apnea, GLP-1 receptor agonists harbor potential beyond weight and diabetes management. In recent years, ...